Department of Sport Medicine, Australian Institute of Sport, Leverrier St, Bruce ACT 2617, Australia.
University of Canberra Research Institute for Sport and Exercise (UCRISE), Cnr Allawoona St & Ginninderra Drive Bruce, ACT 2617, Australia.
Nutrients. 2019 Jan 2;11(1):76. doi: 10.3390/nu11010076.
The current pilot study investigates whether oral supplementation of specific collagen peptides improves symptoms and tendon vascularisation in patients with chronic mid-portion Achilles tendinopathy in combination with structured exercise. Participants were given a placebo or specific collagen peptides (TENDOFORTE) in combination with a bi-daily calf-strengthening program for 6 months. Group AB received specific collagen peptides for the first 3 months before crossing over to placebo. Group BA received placebo first before crossing over to specific collagen peptides. At baseline (T1), 3 (T2) and 6 (T3) months, Victorian Institute of Sports Assessment⁻Achilles (VISA-A) questionnaires and microvascularity measurements through contrast-enhanced ultrasound were obtained in 20 patients. Linear mixed modeling statistics showed that after 3 months, VISA-A increased significantly for group AB with 12.6 (9.7; 15.5), while in group BA VISA-A increased only by 5.3 (2.3; 8.3) points. After crossing over group AB and BA showed subsequently a significant increase in VISA-A of, respectively, 5.9 (2.8; 9.0) and 17.7 (14.6; 20.7). No adverse advents were reported. Microvascularity decreased in both groups to a similar extent and was moderately associated with VISA-A (²:0.68). We conclude that oral supplementation of specific collagen peptides may accelerate the clinical benefits of a well-structured calf-strengthening and return-to-running program in Achilles tendinopathy patients.
本初步研究旨在探究口服特定胶原肽是否能改善慢性中段跟腱腱病患者的症状和腱血管生成,同时结合结构化运动。将参与者分为安慰剂组或特定胶原肽组(TENDOFORTE),并联合每日两次的小腿强化训练,共进行 6 个月。AB 组在前 3 个月接受特定胶原肽治疗,然后交叉到安慰剂组;BA 组则先接受安慰剂治疗,然后交叉到特定胶原肽组。在基线(T1)、3 个月(T2)和 6 个月(T3)时,对 20 名患者进行了维多利亚运动评估⁻跟腱(VISA-A)问卷和对比增强超声的微血管测量。线性混合模型统计分析显示,3 个月后,AB 组的 VISA-A 显著增加 12.6(9.7;15.5)分,而 BA 组仅增加 5.3(2.3;8.3)分。交叉后,AB 组和 BA 组的 VISA-A 分别显著增加 5.9(2.8;9.0)和 17.7(14.6;20.7)分。未报告不良反应。两组的微血管均有相似程度的减少,且与 VISA-A 呈中度相关(²:0.68)。我们得出结论,口服特定胶原肽可能会加速结构化小腿强化和重返跑步方案对跟腱腱病患者的临床获益。